vs
National CineMedia, Inc.（NCMI）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
National CineMedia, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.8倍（$63.4M vs $35.5M），National CineMedia, Inc.净利率更高（2.5% vs -304.2%，领先306.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 1.6%），National CineMedia, Inc.自由现金流更多（$-2.0M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -16.4%）
国家影院传媒是一家美国影院广告企业，依托由AMC、喜满客、 regal等头部连锁影院及区域影院院线组成的影院数字化网络，面向美国消费者，在影院场地、线上渠道以及移动端开展影院广告业务，是美国影院广告领域的核心运营商。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NCMI vs RXRX — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $63.4M | $35.5M |
| 净利润 | $1.6M | $-108.1M |
| 毛利率 | 95.0% | 59.8% |
| 营业利润率 | -2.8% | -304.8% |
| 净利率 | 2.5% | -304.2% |
| 营收同比 | 1.6% | 681.7% |
| 净利润同比 | 144.4% | 39.6% |
| 每股收益（稀释后） | $0.02 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $35.5M | ||
| Q3 25 | $63.4M | $5.2M | ||
| Q2 25 | $51.8M | $19.2M | ||
| Q1 25 | $34.9M | $14.7M | ||
| Q4 24 | $86.3M | $4.5M | ||
| Q3 24 | $62.4M | $26.1M | ||
| Q2 24 | $54.7M | $14.4M | ||
| Q1 24 | $37.4M | $13.8M |
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $1.6M | $-162.3M | ||
| Q2 25 | $-10.7M | $-171.9M | ||
| Q1 25 | $-30.7M | $-202.5M | ||
| Q4 24 | $24.7M | $-178.9M | ||
| Q3 24 | $-3.6M | $-95.8M | ||
| Q2 24 | $-8.7M | $-97.5M | ||
| Q1 24 | $-34.7M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | 95.0% | -183.8% | ||
| Q2 25 | 93.8% | -4.9% | ||
| Q1 25 | 91.1% | -48.0% | ||
| Q4 24 | 96.4% | -181.4% | ||
| Q3 24 | 94.7% | 53.7% | ||
| Q2 24 | 93.2% | 36.2% | ||
| Q1 24 | 90.4% | 19.1% |
| Q4 25 | — | -304.8% | ||
| Q3 25 | -2.8% | -3327.6% | ||
| Q2 25 | -23.2% | -916.8% | ||
| Q1 25 | -68.5% | -1297.9% | ||
| Q4 24 | 23.2% | -4042.4% | ||
| Q3 24 | -12.0% | -377.1% | ||
| Q2 24 | -17.0% | -697.4% | ||
| Q1 24 | -60.7% | -698.4% |
| Q4 25 | — | -304.2% | ||
| Q3 25 | 2.5% | -3135.3% | ||
| Q2 25 | -20.7% | -894.2% | ||
| Q1 25 | -88.0% | -1373.3% | ||
| Q4 24 | 28.6% | -3935.5% | ||
| Q3 24 | -5.8% | -367.5% | ||
| Q2 24 | -15.9% | -676.6% | ||
| Q1 24 | -92.8% | -662.4% |
| Q4 25 | — | $-0.17 | ||
| Q3 25 | $0.02 | $-0.36 | ||
| Q2 25 | $-0.11 | $-0.41 | ||
| Q1 25 | $-0.32 | $-0.50 | ||
| Q4 24 | $0.26 | $-0.56 | ||
| Q3 24 | $-0.04 | $-0.34 | ||
| Q2 24 | $-0.09 | $-0.40 | ||
| Q1 24 | $-0.36 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.9M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $350.5M | $1.1B |
| 总资产 | $451.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | — | $743.3M | ||
| Q3 25 | $29.9M | $659.8M | ||
| Q2 25 | $37.2M | $525.1M | ||
| Q1 25 | $59.8M | $500.5M | ||
| Q4 24 | $75.2M | $594.4M | ||
| Q3 24 | $49.5M | $427.6M | ||
| Q2 24 | $53.8M | $474.3M | ||
| Q1 24 | $57.1M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | — | $1.1B | ||
| Q3 25 | $350.5M | $1.0B | ||
| Q2 25 | $350.0M | $919.1M | ||
| Q1 25 | $370.8M | $933.9M | ||
| Q4 24 | $411.2M | $1.0B | ||
| Q3 24 | $385.5M | $524.6M | ||
| Q2 24 | $387.9M | $584.4M | ||
| Q1 24 | $402.3M | $401.2M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $451.9M | $1.4B | ||
| Q2 25 | $462.0M | $1.3B | ||
| Q1 25 | $503.8M | $1.3B | ||
| Q4 24 | $568.6M | $1.4B | ||
| Q3 24 | $526.1M | $726.5M | ||
| Q2 24 | $527.2M | $775.9M | ||
| Q1 24 | $538.6M | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.0M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $-47.3M |
| 自由现金流率自由现金流/营收 | -3.2% | -133.1% |
| 资本支出强度资本支出/营收 | 1.6% | 3.5% |
| 现金转化率经营现金流/净利润 | -0.63× | — |
| 过去12个月自由现金流最近4个季度 | $24.8M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-46.1M | ||
| Q3 25 | $-1.0M | $-117.4M | ||
| Q2 25 | $-4.9M | $-76.4M | ||
| Q1 25 | $6.0M | $-132.0M | ||
| Q4 24 | $30.5M | $-115.4M | ||
| Q3 24 | $-2.0M | $-59.2M | ||
| Q2 24 | $7.7M | $-82.2M | ||
| Q1 24 | $24.1M | $-102.3M |
| Q4 25 | — | $-47.3M | ||
| Q3 25 | $-2.0M | $-117.6M | ||
| Q2 25 | $-6.6M | $-79.6M | ||
| Q1 25 | $5.3M | $-133.8M | ||
| Q4 24 | $28.1M | $-116.7M | ||
| Q3 24 | $-2.6M | $-63.8M | ||
| Q2 24 | $6.4M | $-83.4M | ||
| Q1 24 | $22.6M | $-109.0M |
| Q4 25 | — | -133.1% | ||
| Q3 25 | -3.2% | -2272.5% | ||
| Q2 25 | -12.7% | -413.9% | ||
| Q1 25 | 15.2% | -907.4% | ||
| Q4 24 | 32.6% | -2567.7% | ||
| Q3 24 | -4.2% | -244.6% | ||
| Q2 24 | 11.7% | -578.5% | ||
| Q1 24 | 60.4% | -789.9% |
| Q4 25 | — | 3.5% | ||
| Q3 25 | 1.6% | 4.7% | ||
| Q2 25 | 3.3% | 16.4% | ||
| Q1 25 | 2.0% | 12.4% | ||
| Q4 24 | 2.8% | 28.6% | ||
| Q3 24 | 1.0% | 17.5% | ||
| Q2 24 | 2.4% | 8.2% | ||
| Q1 24 | 4.0% | 48.2% |
| Q4 25 | — | — | ||
| Q3 25 | -0.63× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.23× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NCMI
| National Advertising Revenue | $49.9M | 79% |
| Local Advertising Revenue | $9.6M | 15% |
| Founding Member Advertising Revenue From Beverage Concessionaire Agreements | $3.9M | 6% |
RXRX
暂无分部数据
